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Summary
At neuromuscular synapses, neural agrin (n-agrin) stabilizes embryonic postsynaptic acetylcholine receptor (AChR) clusters by
signalling through the muscle-specific kinase (MuSK) complex. Live imaging of cultured myotubes showed that the formation and
disassembly of primitive AChR clusters is a dynamic and reversible process favoured by n-agrin, and possibly other synaptic signals.
Neuregulin-1 is a growth factor that can act through muscle ErbB receptor kinases to enhance synaptic gene transcription. Recent studies
suggest that neuregulin-1–ErbB signalling can modulate n-agrin-induced AChR clustering independently of its effects on transcription.
Here we report that neuregulin-1 increased the size of developing AChR clusters when injected into muscles of embryonic mice. We
investigated this phenomenon using cultured myotubes, and found that in the ongoing presence of n-agrin, neuregulin-1 potentiates
AChR clustering by increasing the tyrosine phosphorylation of MuSK. This potentiation could be blocked by inhibiting Shp2, a
postsynaptic tyrosine phosphatase known to modulate the activity of MuSK. Our results provide new evidence that neuregulin-1
modulates the signaling activity of MuSK and hence might function as a second-order regulator of postsynaptic AChR clustering at the
neuromuscular synapse. Thus two classic synaptic signalling systems (neuregulin-1 and n-agrin) converge upon MuSK to regulate
postsynaptic differentiation.
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Introduction
At mature neuromuscular junctions (NMJs), acetylcholine
receptors (AChRs) are clustered at high density (,10,000/mm2)
in direct apposition to presynaptic neurotransmitter release sites
(Fertuck and Salpeter, 1974; Fertuck and Salpeter, 1976). High
density AChR clustering results from: the entrapment of diffuse
pre-existing AChRs in the postsynaptic membrane; upregulation
of the transcription of AChR subunit genes in the synaptic region
and downregulation of the transcription of AChR subunit genes
in the extra-synaptic region (Brenner et al., 1990; Merlie and
Sanes, 1985; Sanes and Lichtman, 1999). At the NMJ, neural
agrin (n-agrin) signals through the muscle-specific kinase
(MuSK) by binding its co-receptor, low-density lipoprotein
receptor (LDLR)-related protein (LRP4) receptor, to stabilize
AChR clusters in the muscle membrane (Ghazanfari et al., 2010;
Kim et al., 2008; Valenzuela et al., 1995; Zhang et al., 2008). N-
agrin binding to LRP4 enhances LRP4–MuSK interaction leading
to autophosphorylation and activation of MuSK (Ghazanfari et al.,
2010; Glass et al., 1996; Lin et al., 2008; Zhang et al., 2008).
Activation of MuSK triggers positive and negative feedback
loops that regulate the phosphorylation (activation) of MuSK,
and consequently the degree of AChR clustering. Positive
feedback is triggered when MuSK causes the tyrosine
phosphorylation of Abl 1/2 and Src-family kinases (Finn et al.,
2003; Smith et al., 2001) with Abl kinases acting on MuSK to
further increase MuSK phosphorylation and drive AChR
clustering (Mittaud et al., 2004). Negative feedback is initiated
when MuSK activates Shp2, a tyrosine phosphatase that acts to
de-phosphorylate MuSK, resulting in a reduction of AChR
clustering (Camilleri et al., 2007; Madhavan and Peng, 2005;
Madhavan et al., 2005; Qian et al., 2008; Zhao et al., 2007).
Hence, Abl kinases and Shp2 are in a position to regulate n-
agrin–MuSK-mediated AChR clustering by modulating the
activity of the MuSK receptor.
The developmental and physiological role of neuregulin-1 at
the neuromuscular synapse has remained contentious for many
years. Neuregulin-1 is a trans-synaptic growth and differentiation
factor that signals through ErbB kinase receptors to increase the
transcription of synaptic genes such as those for AChRa, AChRe
and utrophin (Brenner et al., 1990; Chu et al., 1995; Jo et al.,
1995; Martinou et al., 1991; Moscoso et al., 1995; Ngo et al.,
2004). However, animals with either nerve-specific knockout of
neregulin-1 or muscle-specific knockout of its receptor ErbB2/4
exhibit largely normal adult synapses, throwing into doubt the
role of neuregulin-1 in synapse formation (Escher et al., 2005;
Fricker et al., 2011; Jaworski and Burden, 2006). Recent muscle
culture experiments have reported that neuregulin-1 can either
potentiate AChR clustering (Ngo et al., 2004) or de-stabilize
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existing AChR clusters (Trinidad and Cohen, 2004); however, the
mechanisms remain unclear and the apparently conflicting results
of these two studies have not been resolved. There is evidence
that neuregulin-1–ErbB and n-agrin–MuSK signalling pathways
might interact. Both pathways can influence postsynaptic gene
transcription, and both possess common second messengers (e.g.
Cdk5 and Shp2) involved in stabilizing AChR clusters (Fu et al.,
2005; Ip et al., 2000; Lacazette et al., 2003; Lin et al., 2005; Qian
et al., 2008; Zhao et al., 2007). There is reason to think that
n-agrin–MuSK and neuregulin-1–ErbB signalling pathways
converge to modulate AChR clustering (Chen et al., 2007; Lin
et al., 2005; Ngo et al., 2004; Ngo et al., 2007; Qian et al., 2008;
Zhao et al., 2007).
Here we show that, under conditions where n-agrin is limiting,
neuregulin-1 potentiated n-agrin-induced AChR cluster formation
over a short time frame (4 hours) both in vivo and in vitro.
In response to prolonged exposure (12 hours) neuregulin-1
accelerated the disassembly of established n-agrin-induced AChR
clusters. The acute potentiation of n-agrin-induced AChR cluster
formation involved enhanced MuSK phosphorylation. Neuregulin-
1 might serve as a second-order regulator, modulating n-agrin
signalling at the synapse during development and in response to
physiological challenges.
Results
Exogenous neuregulin-1 increases the size of AChR
clusters in vivo
Based on our previous findings that neuregulin-1 can potentiate
n-agrin-induced AChR clustering in vitro (Ngo et al., 2004), we
sought to determine whether it might do something similar in
embryonic muscles. N-agrin, produced by embryonic motor
neurons is transported to the nerve terminal where it is essential
for stabilizing newly forming postsynaptic AChR clusters (Cohen
and Godfrey, 1992; Gautam et al., 1996; Magill-Solc and
McMahan, 1988; McMahan, 1990; Reist et al., 1992). Because
of the early expression of neuregulin-1 at the developing
neuromuscular synapses of both chick and mouse (Loeb et al.,
1999; Meyer et al., 1997), we hypothesized that neuregulin-1
might be capable of influencing AChR clustering at this early
stage of synapse formation. We investigated the expression
of neuregulin-1 receptors in embryonic day (E) 15 mouse
sternomastoid muscle, and found that ErbB2 was present over the
muscle surface and was coextensive with AChR clusters
(Fig. 1A–C, synaptic and extra-synaptic). By contrast, ErbB3
immunostaining appeared to be restricted to the synaptic region,
coextensive with AChRs, with a slight shift to the presynaptic
side of the AChR cluster (Fig. 1D–F), suggesting that some of the
Fig. 1. Exogenous neuregulin-1 increases the size of
AChR clusters in vivo. (A–C) Immunofluorescence
staining in E15 sternomastoid muscle reveals ErbB2 to be
present over the muscle surface and co-extensive with
AChRs. (D–F) ErbB3 expression is restricted to AChR-
rich regions with a slight shift to the pre-synaptic side of
AChR cluster (F), suggesting that some of the ErbB
staining is presynaptic. Scale bar: 20 mm. (G) The
sternomastoid muscles of E15 mouse embryos were
injected in utero with recombinant neuregulin-1 protein
(33 nM). AChR cluster size was quantified 4 hours post
injection. The frequency histogram summarizes the
number of observations per binned AChR size between
PBS- and neuregulin-1-injected embryos. Exogenous
neuregulin-1 protein significantly increased AChR cluster
size when compared with PBS-injected controls
(P,0.0001, 1183 AChR clusters for PBS injections
across five embryos and 1826 AChR clusters for
neuregulin-1 injections across five embryos; Mann–
Whitney U-test). (H,I) Sample images of AChR clusters
in a control PBS–injected embryo (H) and neuregulin-1
injected embryo (I). (J) Muscle cross-sectional area of
PBS- and neuregulin-1-injected muscles. Values are
means 6 s.e.m. Injection of neuregulin-1 did not change
the cross-sectional area of muscle fibres. (K,L) Sample
images from PBS-injected (K) and neuregulin-1-injected
(L) muscles re-stained for the presence of AChRs (Alexa-
Fluor-555–a-BTX, red) and motor nerve endings (anti-
neurofilament and anti-synaptophysin cocktail, green).
(M) Quantification of the percentage of AChR clusters
associated with motor nerve endings (means 6 s.e.m.;
P50.5115, n56 PBS-injected embryos and n55
neuregulin-injected embryos, unpaired t-test). Scale bars:
50 mm (H–L).
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ErbB3 is presynaptic. Subsequently, using ultrasound bio-
microscopy, sternomastoid muscles of mouse embryos were
injected with either phosphate-buffered saline (PBS; Fig. 1H) or
recombinant neuregulin-1 protein (33 nM) combined with
FluoresbriteH Yellow Green Microspheres (Fig. 1I) during this
period of synapse formation (E15) (Lupa and Hall, 1989; Noakes
et al., 1993). We examined a 100 mm region surrounding the
injection site (identified by fluorescent beads, not shown). Four
hours after the injection there was a significant increase in the
mean area of AChR clusters in neuregulin-1-injected muscles
compared with PBS-injected controls [12.33 mm2 with PBS and
30.80 mm2 (mean values) with neuregulin-1; P,0.0001, 1183
AChR clusters for PBS injections across five embryos (n55) and
1826 AChR clusters for neuregulin-1 injections across 5 embryos
(n55); Mann–Whitney U-test; Fig. 1G]. This increase in AChR
cluster area was not a result of muscle hypertrophy as there was
no increase in the cross-sectional area of muscle cells (Fig. 1J).
There was no significant change in the proportion of AChR
clusters associated with nerve staining [i.e. AChRs that were
#5 mm away from neurofilament-synaptophysin-stained nerves
(Fig. 1K–M), P50.5115, n56 embryos for PBS and n55
embryos for neuregulin-1, unpaired t-test]. Nor was there any
increase in the total number of AChR clusters between PBS-
injected and neuregulin-1-injected embryos (P50.0614, n55
embryos per group, unpaired t-test). Hence, neuregulin-1 would
appear to enhance the growth of pre-existing synaptic AChR
clusters in these developing muscles (Fig. 1G).
Life-cycle of AChR cluster formation and disassembly
When n-agrin is added to cultured myotubes the number of
AChR clusters first rises, reaching a peak after 4 hours, then
declines at later time points (Ferns et al., 1996; Ngo et al., 2004).
To gain a clearer idea of the dynamics of AChR clustering, we
used the C2C12 myoblast cell line and time-lapse imaging to
follow the life cycle of the largest AChR cluster that formed on
each of nine myotubes over 12 hours of n-agrin treatment. AChR
clusters were defined as discrete, uninterrupted areas of intense
a-bungarotoxin fluorescence, typically extending along the long
axis of the myotube. Images were taken at 10-minute intervals
(Fig. 2A). At 4 hours, six large clusters were fully assembled
(Fig. 2A). Cluster number one arose from the coalescence of
smaller AChR clusters between 40 and 210 minutes after the
Fig. 2. N-agrin causes time-dependent AChR clustering and
disassembly. Time-lapse studies were conducted on C2C12
myotubes treated with 10 nM n-agrin for 12 hours. AChRs were
considered to be a large AChR cluster when they were $25 mm
in their longest dimension (i.e. uninterrupted staining of the
longest dimension in the cluster $25 mm). (A) Time-lines
summarizing the formation and dispersal of nine large AChR
clusters during prolonged treatment with n-agrin. AChR
clusters formed from the coalescence of small AChR clusters
and survived 49611 minutes before breaking up into smaller
AChR clusters. Sometimes the established large AChR cluster
(red rectangle) transiently split into two large AChR clusters
(cluster 4) or smaller AChR clusters before reassembly of the
smaller fragment AChR clusters into a single large AChR
cluster (cluster 5) or two large clusters (clusters 2, 3 and 7).
(B) Time-lapse images showing the formation of a large AChR
cluster (cluster 1 in A; white large arrow) from small AChR
clusters (yellow arrows) and the subsequent dispersal into small
AChRs (green arrowheads) between 30 and 490 minutes. Scale
bar: 25 mm. Time in minutes is given in each panel. The
vertical line through the 4-hour time point in A, indicates that at
4 hours, six out of the nine AChR clusters were classified as
large clusters.
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addition of n-agrin (Fig. 2A,B). The resultant large cluster
remained intact for approximately 1.5 hours before progressively
breaking up into smaller clusters over the subsequent 3 hours.
The life-cycles of large AChR clusters fell into three stages
(summarized in Fig. 2A): (1) the formation of small AChR
clusters; (2) coalescence of a group of such small AChR clusters
into a large AChR cluster; and (3) subsequent fragmentation of
the large cluster into smaller AChR clusters. In each instance the
formation of large AChR clusters resulted from the coalescence
of small AChR clusters in the immediate vicinity of where the
large AChR cluster would subsequently form. A large contiguous
AChR cluster (largest clusters ranging from 41 to 273 mm2) arose
from the aggregation of several smaller AChR clusters (Fig. 2B,
30–210 minutes). The formation of each large AChR cluster
occurred approximately 2–6 hours after the appearance of small
AChR clusters.
Of the nine large AChR clusters tracked, none survived intact
for more than 90 minutes before breaking up into smaller AChR
clusters. In five of the nine cases, the break-up of the large single
AChR cluster was followed by the formation of two large AChR
clusters (cluster 4) or a transient partial or complete reassembly
of the smaller fragment AChR clusters into a single large AChR
cluster (cluster 5) or two large clusters (cluster numbers 2, 3 and
7), prior to final disassembly (Fig. 2A). By the end of the 12-hour
imaging period, all but three of the large clusters had broken
down into small clusters, or had completely dispersed (Fig. 2A).
Thus, in C2C12 myotubes at least, n-agrin instigates a process
that involves an initial formation of small AChR clusters, these
then coalesce to form a larger AChR cluster that subsequently
breaks up into smaller AChR clusters (Fig. 2). Factors that
influence the number and size of large n-agrin-induced AChR
clusters might then act at any or all of these transition points in
the life cycle of the primitive AChR cluster. Notably there was a
time-dependent shift, occurring roughly 4 hours after the addition
of n-agrin, from an initial tendency of AChR cluster assembly,
toward disassembly. This is in line with previous studies that
have quantified the number of large n-agrin-induced AChR
clusters at this time-point (Ferns et al., 1996; Ngo et al., 2004).
Thus agents that act acutely to enhance assembly of AChR
clusters could have different effects when applied for prolonged
periods.
Neuregulin-1 modulates AChR cluster formation and
disassembly
Our previous work showed that neuregulin-1 could potentiate n-
agrin-induced AChR clustering in C2C12 myotubes (Ngo et al.,
2004), whereas others have reported that neuregulin-1
disassembled C2C12 AChR clusters over a longer time frame
(Trinidad and Cohen, 2004). To address this apparent
contradiction, we repeated our experiments and compared short
and long treatment periods. We used a concentration of n-agrin
that produced half-maximal AChR clustering (1 nM) in
combination with a concentration of neuregulin-1 (3 nM)
sufficient to induce AChRe subunit gene (Chrne) transcription
(Ngo et al., 2004). In the continued presence of n-agrin, addition
of neuregulin-1 over a 4-hour treatment period produced a 1.6-
fold increase in the number of large AChR clusters ($25 mm in
length) per myotube segment compared with myotubes treated
with half-maximal n-agrin alone (Fig. 3A). The same treatments
applied for 12 hours produced very different results. Myotubes
treated with 1 nM n-agrin for 12 hours retained only one third the
number of large ($25 mm) AChR clusters present after 4 hours
of treatment (Fig. 3A,B). This is consistent with the observation
that the number of large AChR clusters peaked at approximately
4 hours of n-agrin treatment and subsequently declined (Fig. 2)
(Ngo et al., 2004). These results extend our observations that
there is a time-dependent loss of large AChR clusters in cultures
continually exposed to n-agrin. Importantly, the observed loss of
large AChR clusters from myotubes was greater (2.4-fold) when
neuregulin-1 (3 nM) was added in the ongoing presence of n-
agrin (Fig. 3B). These results suggest that neuregulin-1 can
augment the n-agrin-induced formation of AChR clusters (a rapid
Fig. 3. Neuregulin-1 modulates n-agrin-induced
AChR clustering. The formation and dispersal of
large AChR clusters ($25 mm) was analyzed in
mouse myotubes treated with continuous n-agrin
(AGR) plus or minus neuregulin-1 (NRG) for
either 4 or 12 hours. (A) In C2C12 myotubes,
neuregulin-1 potentiated the number of AChR
clusters formed over 4 hours in response to a sub-
maximal concentration (1 nM) of n-agrin (bars 2
and 3, P,0.0001, n53, ANOVA). (B) In C2C12
cultures, neuregulin-1 exacerbated the loss of
AChR clusters over 12 hours when compared with
n-agrin treatment alone (bars 2 and 3, P,0.0001,
n53, ANOVA). (C) In primary myotubes,
neuregulin-1 again caused a strong potentiation of
n-agrin-induced (1 nM) AChR clustering in the
first 4 hours of exposure (bars 2 and 3, P,0.005,
n53, ANOVA). (D) In primary myotubes exposed
to n-agrin for 12 hours, neuregulin-1 exacerbated
the loss of AChR clusters (bars 2 and 3, P,0.0005,
n53, ANOVA). 1 and 1051 nM and 10 nM
respectively. Different lowercase letters indicate
significant differences between groups. Values are
means 6 s.e.m.
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event) but also accelerate AChR cluster disassembly when
applied for a longer time.
Because C2C12 cells are an immortalized cell line,
experiments were repeated in primary mouse muscle cultures.
Primary myotubes treated with 1 nM n-agrin and 3 nM
neuregulin-1 for 4 hours exhibited a significant (P,0.005)
increase in the number of large ($25 mm) AChR clusters
compared with half-maximal n-agrin treatment alone (Fig. 3C).
Over 12 hours, and in the continued presence of n-agrin, 3 nM
neuregulin-1 also caused a significantly greater (P,0.0005) loss
of large AChR clusters than half-maximal n-agrin treatment
alone (Fig. 3D). These results were similar to what we observed
in C2C12 cultures (Fig. 3A,B), although large AChR clusters on
primary myotubes appeared somewhat more stable over the 12-
hour treatment period than those on C2C12 myotubes (compare
Fig. 3B with 3D). These results in primary cultures confirm the
ability of neuregulin-1 to potentiate n-agrin-induced AChR
clustering and to exacerbate AChR cluster loss over longer
treatment times.
Neuregulin-1 potentiates n-agrin-induced AChR clustering
through ErbB2
In order to determine whether neuregulin-1 potentiation of n-
agrin-induced AChR clustering occurred through a neregulin-1–
ErbB receptor interaction, we first identified the expression of
ErbB receptors on C2C12 myotubes. Previous studies showed
that ErbB2 receptors are expressed in C2C12 myotubes (Jo et al.,
1995). Using immunofluorescence, we identified ErbB2 adjacent
to or within the vicinity of n-agrin-induced AChR clusters
(Fig. 4A). Given the proximity of ErbB2 to AChRs, we next
examined whether neuregulin-1 acts through ErbB2 to potentiate
n-agrin-induced AChR clustering. To address this, we used the
ErbB2 inhibitor PD168393 (Calvo et al., 2011). C2C12 myotubes
were cultured with 1 nM n-agrin in the presence or absence of 3
nM neuregulin-1, and each of these were tested in the presence
or absence of 10 mM PD168393 (Fig. 4B). Treatment with
PD168393 alone for 4 hours produced no AChR clusters
(Fig. 4B, bar 6). In the presence of 1 nM n-agrin, PD168393
did not alter the number of AChR clusters compared with n-agrin
treatment alone (Fig. 4B, bars 1 and 3). As previously shown,
treatment of myotubes with 1 nM n-agrin and 3 nM neuregulin-1
led to an increase in the number of large AChR clusters compared
with n-agrin treatment alone (Fig. 4B, bars 1 and 2). In the
presence of PD168393, however, neuregulin-1 was no longer
able to induce a significant increase in the number of large n-
agrin-induced AChR clusters (Fig. 4B, bars 2 and 4). Hence,
neuregulin-1 potentiates n-agrin-induced AChR clustering
through the ErbB2 receptor.
Neuregulin-1 can act only in unison with n-agrin
Soluble isoforms of neuregulin-1 become concentrated at
developing synapses by their interaction with heparan sulphate
proteoglycans (HSPGs) (Loeb et al., 1999). Given that n-agrin is
a HSPG, we next examined whether the n-agrin-induced AChR
clustering potentiated by neuregulin-1 required the concurrent
presence of n-agrin. Previous work showed that a brief
(5 minutes) exposure to n-agrin was sufficient to induce
maximal AChR clustering (Mittaud et al., 2004). We tested the
effect of pulsed exposure of myotubes to 1 nM n-agrin on the
number of large ($25 mm) AChR clusters 4 hours after the pulse
treatment. In agreement with Mittaud et al. a 5-minute n-agrin
pulse treatment of C2C12 myotubes led to significant (P,0.01)
subsequent AChR cluster formation (Mittaud et al., 2004).
However, we found that a single 5-minute or 10-minute pulse of
1 nM n-agrin produced significantly fewer large AChR clusters
than continual exposure to 1 nM n-agrin over the full 4-hour
period (Fig. 5A).When the 5-minute treatment with 1 nM n-agrin
was replaced with 3 nM neuregulin-1 for the remaining 4 hours,
there was no change in the number of large AChR clusters
compared with myotubes treated with n-agrin alone for 5 minutes
(Fig. 5B). Neuregulin-1 only potentiated n-agrin-induced AChR
cluster formation when myotubes were concurrently exposed to
neuregulin-1 and n-agrin.
Expression levels of synaptic mRNA transcripts
Neuregulin-1 has previously been shown to induce AChR subunit
gene transcription in muscle cells (Brenner et al., 1990; Chu et al.,
1995; Martinou et al., 1991; Ngo et al., 2004). It has been
suggested that n-agrin can also influence AChR and MuSK
gene expression. We therefore examined the possibility that
neuregulin-1 might potentiate n-agrin-induced AChR clustering
indirectly, by increasing the expression of mRNAs encoding
AChRa subunit and MuSK. C2C12 myotubes were treated for
4 hours with n-agrin (1 nM) in the presence or absence of
neuregulin-1 (3 nM) and mRNA levels were then analyzed. Over
4 hours, none of the treatments produced any significant change
in the levels of AChR and MuSK mRNA transcripts relative to
untreated controls (supplementary material Fig. S1). These
findings suggest that neuregulin-1 potentiates n-agrin-induced
Fig. 4. Neuregulin-1 potentiates n-agrin-induced AChR clustering
through ErbB2. (A) ErbB2 receptor immunostaining (green) and AChR
clusters (red) are coexpressed on the surface of C2C12 myotubes after 4 hours
n-agrin treatment. Scale bar: 20 mm. (B) A 4-hour treatment of myotubes with
n-agrin (AGR, 1 nM) plus neuregulin-1 (NRG, 3 nM) led to a significant
potentiation in AChR cluster number compared with n-agrin treatment alone
(bars 1 and 2, P,0.0001, n53, ANOVA). In the presence of the ErbB2
inhibitor, PD168393 (PD, 10 mM), neuregulin-1 was no longer able to
potentiate n-agrin-induced AChR clustering (compare bar 2 with bar 4;
P,0.0001, n53, ANOVA). Different lowercase letters indicate significant
differences between groups at P,0.0001. Bars with the same superscript are
not significantly different. Values are means 6 s.e.m.
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AChR clustering in a manner that is independent of transcription.
Our results do not exclude the longer-term effects of neuregulin-1
reported by others (after overnight treatment) or the effects of n-
agrin in cultures of avian muscle (Brenner et al., 1990; Chu et al.,
1995; Lacazette et al., 2003; Li and Loeb, 2001; Martinou et al.,
1991; Ngo et al., 2004).
Neuregulin-1 potentiation of AChR clustering does not
depend upon calpain or cyclin-dependent kinase 5
Calpain and Cdk5 are involved in a partially defined pathway of
AChR cluster disassembly (Chen et al., 2007; Lin et al., 2005).
Calpain functions upstream of Cdk5 in the acetylcholine-induced
disassembly of AChR clusters (Chen et al., 2007). We therefore
wanted to determine whether neuregulin-1 impinged upon this
pathway. To address this, we first used the calpain inhibitor,
calpeptin (Tsujinaka et al., 1988). C2C12 myotubes were
cultured with 1 nM n-agrin in the presence or absence of 3 nM
neuregulin-1, and each of these were tested in the presence or
absence of 20 mM calpeptin (Fig. 6A). Treatment with calpeptin
alone for 4 hours produced no AChR clusters (Fig. 6A, bar 6),
but in the presence of 1 nM n-agrin, calpeptin increased the
number of AChR clusters compared with the number obtained
with 1 nM n-agrin alone (Fig. 6A, bars 1 and 3). Nevertheless,
in the presence of calpeptin, neuregulin-1 still produced a
significant (P,0.001) further potentiation of n-agrin-induced
AChR clustering (Fig. 6A, bars 3 and 4).
Next we used the Cdk5 inhibitor, roscovitine (2 mM), to
investigate the involvement of Cdk5 (Meijer et al., 1997). C2C12
myotubes were treated for 4 hours with 1 nM n-agrin with or
without 3 nM neuregulin-1 in the presence or absence of
roscovitine. Over this 4-hour period, roscovitine did not alter the
number of large AChR clusters ($25 mm) induced by n-agrin
(Fig. 6B, bars 1and 3), nor did roscovitine affect the potentiation
of AChR clustering by neuregulin-1 (Fig. 6B, bars 2 and 4).
These results suggest that neuregulin-1 potentiation of n-agrin-
induced AChR clustering is independent of the calpain–Cdk5
pathway described previously.
Neuregulin-1 potentiates tyrosine phosphorylation of
MuSK
N-agrin-induced AChR clustering requires tyrosine
phosphorylation of MuSK (Herbst and Burden, 2000). We
Fig. 5. The potentiation of AChR clustering by neuregulin-1 requires n-agrin. (A) Pulse treatment of C2C12 myotubes with 1 nM n-agrin for 5 or 10 minutes
induced significant numbers of large AChR clusters ($25 mm, P,0.01, n53, ANOVA) when counted 4 hours later. Treatment with 1 nM n-agrin for 4 hours
resulted in higher numbers of AChR clusters (P,0.01, n53, ANOVA). (B) When pulse treatment with 1 nM n-agrin (AGR) for 5 minutes was followed
by a 4-hour treatment with neuregulin-1 (NRG, 3 nM, in the absence of n-agrin), no potentiation was found in the number of large AChR clusters ($25 mm,
compare bars 2 and 3). Thus, neuregulin-1 was able to increase the number of n-agrin-induced AChR clusters ($25 mm) only when myotubes were exposed
concurrently to n-agrin (1 nM; P,0.005, n53, ANOVA). Different lowercase letters indicate significant differences between groups. Values are means 6 s.e.m.
Fig. 6. Inhibitors of calpain and Cdk5 do not block potentiation of n-agrin AChR clustering by neuregulin. C2C12 myotubes were treated for 4 hours with
n-agrin (AGR, 1 nM) with or without neuregulin-1 (NRG, 3 nM) in the presence or absence of inhibitors of calpain or roscovitine. (A) In the presence of the
calpain inhibitor, calpeptin (CAL, 20 mM), neuregulin-1 was still able to potentiate n-agrin-induced AChR clustering (bars 3 and 4; P,0.001, n54,
ANOVA). (B) In the presence of the Cdk5 inhibitor roscovitine (ROS, 2 mM), potentiation by neuregulin-1 of n-agrin-induced AChR clustering was unimpaired
(bars 2 and 4). Different lowercase letters indicate significant differences between groups with P,0.001. Values are means 6 s.e.m.
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therefore assessed the tyrosine phosphorylation of MuSK in
response to a 20-minute treatment with 1 nM n-agrin with or
without 3 nM neuregulin-1. MuSK was immunoprecipitated from
cell lysates and the degree of MuSK phosphorylation was
expressed as a percentage of phosphorylation in response to 10
nM n-agrin treatment (Fig. 7B).
As expected, MuSK phosphorylation was not detectable in
control (untreated) myotubes (Fig. 7A, upper panel, lane 1; 7B,
bar 5), whereas 1 nM n-agrin treatment induced MuSK
phosphorylation (Fig. 7A, upper panel, lane 2; 7B, bar 2).
Addition of 3 nM neuregulin-1 concurrently with 1 nM n-agrin
further increased MuSK phosphorylation compared with myotubes
treated with 1 nM n-agrin alone (Fig. 7A, upper panel, compare
lanes 2 with 4; 7B, compare bars 2 and 3). Myotubes treated with
neuregulin-1 alone showed no detectable MuSK phosphorylation
(Fig. 7A, upper panel, lane 5; 7B, bar 4). These results confirm that
n-agrin increases MuSK phosphorylation. Moreover, they show
that when myotubes were treated with sub-maximal concentrations
of n-agrin, neuregulin-1 was able to potentiate n-agrin-induced
phosphorylation of MuSK, just as it is able to potentiate n-agrin-
induced AChR clustering.
Blocking Shp2 function attenuates the potentiation of AChR
clustering and MuSK phosphorylation by neuregulin-1
Recent studies have identified the protein tyrosine phosphatase
Shp2 as a negative regulator of AChR clustering. Activation of
MuSK by n-agrin led to the activation of Shp2, which then acted
to repress excessive MuSK phosphorylation (Madhavan et al.,
2005). We examined the effect of a 4-hour treatment with
neuregulin-1 on n-agrin-induced AChR cluster formation in the
presence of the Shp2 inhibitor, NSC-87877 (1 mM) (Chen et al.,
2006) (Fig. 8A). As previously shown, after 4 hours in the
continuous presence of n-agrin, 3 nM neuregulin-1 potentiated
the number of large AChR clusters formed by 1 nM n-agrin
(Fig. 8A, bars 1 and 2). Addition of the Shp2 inhibitor NSC-
87877 alone did not cause AChR clustering (Fig. 8A, bar 6).
However, in the presence of 1 nM n-agrin, NSC-87877
potentiated n-agrin-induced AChR clustering (Fig. 8A, compare
bars 1 and 3). Furthermore, in the presence of NSC-87877,
neuregulin-1 was unable to produce any further potentiation of n-
agrin-induced AChR clustering (Fig. 8A, compare bars 3 and 4),
thus the ability of neuregulin-1 to potentiate n-agrin-induced
AChR clustering appears to depend upon the function of Shp2
phosphatase.
Because the Shp2 inhibitor NSC-87877 blocked neuregulin-1
potentiation of n-agrin-induced AChR clustering we examined its
effect on MuSK phosphorylation. N-agrin causes rapid MuSK
phosphorylation within 1 hour; long before AChR clustering
reaches its maximal level at 4 hours (Fuhrer et al., 1997). We
therefore examined MuSK phosphorylation in myotubes
20 minutes after the addition of n-agrin and/or neuregulin-1.
MuSK phosphorylation was measured as a percentage of the
phosphorylation in response to 1 nM n-agrin plus 3 nM
neuregulin-1, designated a value of 100% (Fig. 8B, bar 2).
Again, neuregulin-1 significantly increased the n-agrin-induced
tyrosine phosphorylation of MuSK (Fig. 8B, compare bars 1 and
2); however, in the presence of NSC-87877 neuregulin-1 failed to
potentiate n-agrin-induced MuSK phosphorylation (Fig. 8B,
compare bars 2 and 4). Although NSC-87877 appeared to
increase the mean levels of MuSK phosphorylation induced by
either n-agrin or n-agrin plus neuregulin-1 (Fig. 8B, bars 3 and 4
respectively), this was less than that produced by n-agrin
plus neuregulin-1 alone (Fig. 8B, compare bar 2 with bars 3
and 4). NSC-87877 alone did not cause detectable MuSK
phosphorylation (Fig. 8B, bar 5). Together these results suggest
that blocking Shp2 function with NSC-87877 (Zhao et al., 2007)
Fig. 7. Neuregulin-1 potentiates MuSK phosphorylation. C2C12 myotubes were treated for 20 minutes with n-agrin (AGR, 1 nM) with or without neuregulin-1
(NRG, 3 nM). (A) Sample blot showing tyrosine phosphorylation (PY ,110 kDa band; upper panel) of the MuSK band (lower panel). MuSK phosphorylation
was increased in response to n-agrin treatment (upper panel, lane 2). Neuregulin-1 (3 nM) significantly potentiated n-agrin-induced (1 nM) MuSK
phosphorylation (upper panel, compare lanes 2 and 4; P,0.001, n57, ANOVA). No precipitating antibody (-ve ctrl, lane 6) and control human IgG (IgG -ve, lane
7) were included as negative controls. (B) Densitometric quantification of MuSK phosphorylation in response to a 20-minute treatment. Phosphorylation was
detected with 4G10 and immunoblots were stripped and re-probed with anti-MuSK. The integrated pixel intensity value for each phosphorylation band (upper
panel in A) was first normalized to the MuSK protein band (lower panel in A). The normalized integrated pixel values were then compared with the integrated
pixel value of the 10 nM n-agrin-induced MuSK phosphorylation band (designated a value of 100% MuSK phosphorylation). Note the ‘Non specific’ band was
routinely detected under all conditions. Different lowercase letters indicate significant differences between groups; P,0.05 between a and c, and P,0.001 when
comparing b with a and c. Values are means 6 s.e.m.
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inhibits the potentiation of AChR clustering and MuSK
phosphorylation by neuregulin-1.
Discussion
In this study we aimed to clarify the actions of neuregulin-1 on n-
agrin-induced AChR clustering and the underlying molecular
mechanism. We showed that the ability of neuregulin-1 to
potentiate AChR clustering requires that myotubes be
simultaneously exposed to neuregulin-1 and n-agrin. The
potentiation did not involve elevated expression of AChRa or
MuSK mRNAs, rather neuregulin-1 potentiated the tyrosine
phosphorylation of MuSK, a key determinant of downstream
AChR clustering. Neuregulin-1 potentiation of MuSK
phosphorylation and downstream AChR cluster formation were
both blocked by an inhibitor of the tyrosine phosphatase, Shp2, a
known modulator of AChR clustering (Camilleri et al., 2007;
Madhavan et al., 2005; Zhao et al., 2007). Neuregulin-1 was able
to potentiate AChR clustering both in primary cultured muscle
cells and when injected into embryonic muscles in utero
suggesting that the proposed pathway is physiologically relevant.
Neuregulin-1 enhanced AChR cluster formation in embryonic
muscles in vivo and in vitro, presumably through the ErbB2
receptor (Fig. 1A–C; Fig. 4). Injection of neuregulin-1 into
sternomastoid muscles of E15 mouse embryos resulted in a
marked increase in AChR cluster size (4 hours post injection)
compared with control injected embryos. There was a significant
increase in the largest class of AChR clusters, consistent with the
increase in the number of large AChR clusters that we quantified
on cultured myotubes. Our rationale for injecting neuregulin-1 at
E15 was based on the immaturity of the neuromuscular synapse.
E15 is the stage at which neuromuscular synapse formation
begins, a process that is characterized by the appearance of
MuSK and small diffuse AChR clusters (Bowen et al., 1998;
Noakes, 1999; Noakes et al., 1993). At this stage agrin is
‘diffusely distributed’ on the muscle surface (Hoch et al., 1993),
before becoming increasingly concentrated within the synaptic
cleft at later stages (Hoch, 1999; Hoch et al., 1993; Magill-Solc
and McMahan, 1990). Neuregulin-1 is expressed by embryonic
muscle and motor nerve terminals (Loeb, 2003; Loeb et al., 1999;
Meyer et al., 1997). The cognate ErbB receptors are localized
both on the postsynaptic membrane (ErbB2, ErbB3 and ErbB4)
and on Schwann cells (ErbB3) at developing neuromuscular
synapses (Moscoso et al., 1995; Trinidad et al., 2000; Zhu et al.,
1995). We have shown by immunostaining that ErbB2 occurs
synaptically (co-extensive with AChRs) and extra-synaptically
on the muscle surface, at E15 (Fig. 1A–C).
Fig. 8. Blocking Shp2 function attenuates the potentiation of AChR
clustering and MuSK phosphorylation by neuregulin-1. C2C12 myotubes
were treated with n-agrin (AGR, 1 nM) with or without neuregulin-1 (NRG,
3 nM) in the presence or absence of a Shp2 inhibitor (NSC; NSC-87877,
1 mM). (A) Myotubes treated for 4 hours with n-agrin plus neuregulin-1 led to
a potentiation in AChR cluster number compared to n-agrin treatment alone
(bars 1 and 2). In the presence of the Shp2 inhibitor, neuregulin-1 was no
longer able to potentiate n-agrin-induced AChR clusters (compare bar 2 with
bars 3 and 4). Different lowercase letters indicate significant differences
between groups; P,0.001, n53, ANOVA. Values are means 6 s.e.m.
(B) Densitometric quantification of MuSK phosphorylation after treatment of
myotubes for 20 minutes with n-agrin plus neuregulin-1. The integrated pixel
value for each phosphorylation band was normalized to MuSK protein
expression then compared with the integrated pixel value of the 1 nM n-agrin
plus 3 nM neuregulin-1-induced MuSK phosphorylation band (designated a
value of 100% MuSK phosphorylation; bar 2). Treatment of myotubes with 1
nM n-agrin and 3 nM neuregulin-1 resulted in a significant increase in MuSK
phosphorylation compared with 1 nM n-agrin treatment alone (bars 1 and 2;
P,0.05, n53, ANOVA). In the presence of NSC-87877, neuregulin-1 could
no longer potentiate n-agrin-induced MuSK phosphorylation (compare bar 2
to bars 3 and 4; P,0.05, n53, ANOVA). The Shp2 inhibitor alone did not
induce MuSK phosphorylation (bar 5). Different lowercase letters indicate
significant differences between groups. Values are means 6 s.e.m. (C) A
hypothetical model for the potentiation of n-agrin-induced AChR clustering
by neuregulin-1. At the neuromuscular synapse, n-agrin binds to the Lrp4–
MuSK complex, leading to MuSK phosphorylation. Abl and Src kinases help
maintain MuSK phosphorylation levels (Finn et al., 2003; Smith et al., 2001).
Shp2 tyrosine phosphatase dephosphorylates MuSK (Madhavan and Peng,
2005; Madhavan et al., 2005). When ErbB is activated by neuregulin-1, Shp2
binds to the ErbB complex (Tanowitz et al., 1999). We hypothesize that this
interaction of Shp2 with activated ErbB sequesters Shp2 in such a way as to
block the de-phosphorylation of MuSK. This results in higher levels of n-
agrin-induced MuSK phosphorylation.
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By contrast, ErbB3 staining appeared to be restricted to the
synaptic region of the developing neuromuscular synapse,
consistent with its pre-and post-synaptic distributions (Fig. 1D–
F). ErbB2 staining was also detected on cultured muscle cells
(Fig. 4A). Although we cannot rule out a possible indirect effect
of neuregulin-1 acting through terminal Schwann cells in vivo,
this could not explain the ability of neuregulin-1 to potentiate
AChR clustering on isolated muscle cells in culture. The ability
of injected neuregulin-1 to increase AChR cluster size in vivo
suggests that MuSK activation by n-agrin is likely to be sub-
maximal at these early developing synapses. This assumption is
supported by our in vitro experiments, in which we have used a
sub-maximal dose of n-agrin, to demonstrate potentiation of n-
agrin-mediated AChR clustering by neuregulin-1.
Our live imaging results confirm that AChR cluster formation
is a multi-stage, reversible process. Formation of multiple small
AChR clusters (,25 mm long) was followed by their coalescence
into large, continuous AChR clusters ($25 mm long) 2–6 hours
after the addition of n-agrin (Fig. 2A). In the continual presence
of n-agrin for 12 hours, large AChR clusters were seen to break
up into several smaller AChR clusters before finally dissipating
(Fig. 2). The initial AChR cluster assembly depends upon MuSK
kinase activation and rapsyn (DeChiara et al., 1996; Gautam et al.,
1995; Ghazanfari et al., 2010; Sanes and Lichtman, 2001;
Strochlic et al., 2005). The later process of fragmentation might
involve other intracellular signaling systems with the potential
to cause AChR cluster dispersal (e.g. Shp2 and/or calpain-
dependent mechanisms) (Chen et al., 2007; Ghazanfari et al.,
2010; Wu et al., 2010; Zhao et al., 2007). Previous studies have
shown that the maximal number of n-agrin-induced AChR
clusters reached a peak at 4–6 hours after the addition of n-agrin
to the myotube culture (Ferns et al., 1996; Ngo et al., 2004).
During the first 4 hours of n-agrin exposure, AChR cluster
coalescence events predominated (Fig. 2). The previously
reported decline in large AChR cluster numbers after 4 hours
could be explained by an increase in the frequency of
fragmentation events (4–8 hours) and a subsequent drop in the
rate of coalescence events (in the last 4 hours of n-agrin
exposure). It is interesting to note instances where a large
AChR cluster reassembled after breaking up (five of nine
clusters). This suggests there is competition between
simultaneous processes of assembly and fragmentation.
Potentiation by neuregulin-1 of the early-phase of AChR
clustering in C2C12 myotubes occurred only in the presence of
n-agrin, suggesting that it relies upon the interaction of short-
lived signaling events initiated by n-agrin and neuregulin-1.
In vitro, neuregulin-1 potentiation of n-agrin-induced AChR
clustering did not appear to involve its well-established function
of activation of synaptic gene transcription. Neuregulin-1 is
reported to induce AChRe and AChRd subunit gene transcription
when added to cultures of mouse myotubes. In chick myotubes it
is also reported to induce expression of the AChRa subunit and
MuSK genes (Fu et al., 1999; Ip et al., 2000; Martinou et al.,
1991; Ngo et al., 2004). N-agrin has also been reported to induce
the transcription of Musk indirectly by recruiting ErbB receptors
into muscle membrane (Lacazette et al., 2003); however,
upregulation of these genes was either studied in an avian
system or with treatments of 24 hours or longer when studied in
mammalian myotubes (Fu et al., 1999; Ip et al., 2000; Lacazette
et al., 2003; Li and Loeb, 2001; Martinou et al., 1991; Ngo et al.,
2004). This might explain why we found no increase in the
expression of the AChRa subunit and MuSK genes in mouse
C2C12 myotubes after just 4 hours. Although we have not
examined expression of all synaptic genes, the results with MuSK
and AChRa argue against the idea that neuregulin-1 potentiates
n-agrin-induced AChR clustering through its known pathway for
enhancing synaptic gene transcription (Sanes and Lichtman,
2001).
The phosphorylation of MuSK in response to n-agrin appears to
be moderated by a balance of protein tyrosine kinases and
phosphatases (Camilleri et al., 2007; Finn et al., 2003; Madhavan
and Peng, 2005; Zhao et al., 2007). We found that the Shp2
inhibitor NSC-87877 blocked the potentiation of n-agrin-induced
clustering by neuregulin-1. One interpretation involves the
previously hypothesized negative feedback pathway involving
Src, SIRP and Shp2 (Madhavan and Peng, 2005; Zhao et al., 2007).
N-agrin binding to the MuSK complex leads to tyrosine
phosphorylation of SIRPa1 through Src and possibly other
tyrosine kinases. Phosphorylated SIRPa1 in turn activates Shp2
(Zhao et al., 2007), activated Shp2 then serves to limit the extent of
n-agrin-induced MuSK phosphorylation (Madhavan et al., 2005).
We propose that neuregulin-1 treatment potentiates n-agrin-
induced AChR clustering by somehow suppressing this negative
feedback loop (Fig. 8C). In support of this idea, inhibition of Shp2
with NSC-87877 ablated the ability of neuregulin-1 to potentiate n-
agrin-induced MuSK phosphorylation. However, we have not
directly measured the effects of sub-maximal concentrations of
n-agrin (with and without neuregulin-1) upon Shp2 activity in
embryonic muscle cells. In addition, other studies have shown that
NSC-87877, in the concentration range of 0.2–1 mM might also
inhibit Shp1 (Qian et al., 2008). Further studies are needed to
clarify the mode of this proposed inhibition.
The mechanism by which prolonged neuregulin-1 exposure
might accelerate AChR cluster dispersal remains less clear.
Earlier work showed that chronic administration of neuregulin-1
can lead to loss of postsynaptic AChRs at NMJs (Trachtenberg
and Thompson, 1997), and recent studies have shown that
continued activation of ErbB2 receptors in muscle is sufficient to
cause the loss of n-agrin-induced AChR clusters (Ponomareva
et al., 2006). In agreement with previous studies implicating
Cdk5 in AChR cluster disassembly (Ip et al., 2000; Lin et al.,
2005), blocking Cdk5 function with roscovitine partially rescued
overnight neuregulin-1-driven AChR cluster dispersal (data not
shown). We also tested the effect of inhibiting calpain and Shp2
(Chen et al., 2007; Madhavan et al., 2005; Zhao et al., 2007), but
such inhibitors had no effect upon neuregulin-1-induced AChR
cluster dispersal at the 12-hour time-point (data not shown).
Hence, the long-term action of neuregulin-1 on n-agrin-induced
AChR cluster dispersal will require further detailed study.
Fig. 8C summarizes a hypothetical pathway by which
neuregulin-1 might potentiate MuSK activation. Synaptic
neuregulin-1 acts through ErbB receptors on the muscle
cell surface, whereas n-agrin activates postsynaptic MuSK. Abl
and Src kinases provide positive feedback to sustain
the phosphorylation and kinase activity of MuSK. Shp2
phosphatase is also activated downstream of MuSK, but
functions to limit the extent of MuSK phosphorylation
(Madhavan and Peng, 2005). Shp2 occurs in the postsynaptic
membrane but when ErbB is activated by neuregulin-1, Shp2
binds to the ErbB complex (Tanowitz et al., 1999). We
hypothesize that the interaction of Shp2 with activated ErbB
sequesters Shp2 in such a way as to block MuSK
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dephosphorylation (Fig. 8C), resulting in higher levels of n-
agrin-induced MuSK phosphorylation.
Neuregulin-1 potentiation of MuSK-mediated AChR
clustering appears to play a minor role in early development of
the NMJ. When the neuregulin-1 gene was inactivated in both
nerve and muscle, AChR clusters still formed but nerve terminals
withdrew and postsynaptic AChRs were slightly reduced
compared with control embryos (Jaworski and Burden, 2006).
It is possible that the reduction in AChRs in the absence of
synaptic neuregulin-1 might have been an indirect consequence
of the withdrawal of the nerve terminal. This cannot fully explain
the acute growth of AChR clusters (,4 hours) when we injected
neuregulin-1 into muscles of wild-type embryos, nor can it
explain the gradual loss of AChR clusters from the NMJ when
neuregulin-1 was chronically administered to adult wild-type
mice over 5 days (Trachtenberg and Thompson, 1997). Muscle-
specific targeting of the ErbB receptor 2 and 4 genes was
consistent with endogenous neuregulin-1 acting postsynaptically
to enhance AChR clustering, albeit modestly (Escher et al., 2005;
Leu et al., 2003). Targeting of the Shp2 gene in muscle did not
produce any detectable change in AChR cluster size (Dong et al.,
2006). A caveat noted by Dong et al. was that gene targeting did
not completely eliminate Shp2 expression in muscles. Indeed it
can be difficult to be sure of complete inactivation of any gene in
multinucleated muscle fibres (Jaworski et al., 2007; O’Leary
et al., 2007). Expression of the Cre recombinase gene was often
insufficient to completely excise loxP-targeted genes, such as
Shp2, ErbB2 and ErbB4 in multinucleated muscle cells (Dong
et al., 2006; Escher et al., 2005; Jaworski and Burden, 2006; Leu
et al., 2003), and studies that target the inactivation of genes in
specific cells types (such as motor nerve and muscle) do not
address acute action and/or actions of neuregulin-1 at later stages
of NMJ development. This latter point is worth noting, given that
both n-agrin and neuregulin-1 become concentrated in the
synaptic basal lamina of the NMJ after birth (Hoch et al.,
1993; Moscoso et al., 1995).
Although neuregulin-1 signaling appears to be non-essential
for the early development of the NMJ, the NMJ continues active
regeneration throughout life and in response to challenges such as
micro-denervation and reinnervation in situations where MuSK
signaling might not be optimal (Cole et al., 2010; Valdez et al.,
2010; Wilson and Deschenes, 2005). The ability of the
postsynaptic membrane to respond optimally to such challenges
could well involve convergence of n-agrin and neuregulin-1
signaling.
Materials and Methods
Ethical approval
Experiments complied with the policies and regulations regarding animal
experimentation and other ethical matters (Drummond, 2009). Experiments were
approved by the University of Queensland Animal Ethics Committee and were in
accordance with the Queensland Government Animal Research Act 2001,
associated Animal Care and Protection Regulations (2002 and 2008), as well as
the Australian Code of Practice for the Care and Use of Animals for Scientific
Purposes, 7th Edition (National Health and Medical Research Council, 2004).
Reagents
The C2C12 cell line was obtained from the European Collection of Cell cultures
(www.ecacc.org.uk; GBR). Recombinant rat neural-agrin (amino acids 1153–
1959) (Rupp et al., 1992) was purchased from R&D Systems (Minneapolis, MN).
A dose–response assay was conducted for the n-agrin used in this study. Half-
maximal AChR clustering after 4 hours exposure was obtained with approximately
1 nM n-agrin, and 10 nM yielded the maximum number of AChR clusters.
Recombinant human heregulin-b1 (neuregulin-1) consisting of the 30 kDa
extracellular domain (amino acids 1–241) was obtained from Thermo Scientific
(Waltham, MA). Calpeptin was bought from Merck (Whitehouse Station, NJ) and
used to inhibit calpain (Chen et al., 2007). Roscovitine (from Merck) was used to
inhibit Cdk5 (Lin et al., 2005). NSC-87877, a Shp2 inhibitor (Chen et al., 2006)
was obtained from Merck (Zhao et al., 2007). PD168393 was purchased from
Merck and used to inhibit ErbB2 (Calvo et al., 2011). Tetramethylrhodamine
isothiocyanate (TRITC)-conjugated a-bungarotoxin (TRITC–a-BTX; Sigma, St.
Louis, MO) was used at 1:10,000 in differentiation medium. Affinity purified
human MuSK autoantibodies, and sheep anti-MuSK antibodies were used as
described previously (Cole et al., 2010). Other antibodies used in this study were:
monoclonal anti-mouse phosphotyrosine 4G10 (1:1000: Millipore, Billerica, MA);
rabbit anti-sheep IgG HRP (1:2000; Sigma); sheep anti-mouse IgG HRP (1:10,000:
Amersham/GE Healthcare Bio-Sciences Corp., Piscataway, NJ); rabbit anti-bovine
neurofilament 200 (1:1000, Sigma); rabbit anti-human synaptophysin (1:50,
DakoCytomation, Glostrup, Denmark); rabbit anti-ErbB2 and rabbit anti-ErbB3
(1:100; Santa Cruz Biotechnology, Santa Cruz, CA); Alexa-Fluor-488-conjugated
goat anti-rabbit IgG (1:500 to 1:5000) and Alexa-Fluor-555–a-BTX (1:500) from
Invitrogen (Victoria, Australia). For immunostaining experiments, antibodies were
diluted in 2% bovine serum albumin (BSA) in Triton X-100 in PBS, pH 7.4, and
for western blot experiments in 2.5% skimmed milk in 0.05% Tween 20 in Tris-
buffered saline (TBS-T), pH 7.6.
Muscle cell culture and assays
Mouse C2C12 cells and C57Bl/6J mouse primary myotubes were maintained at
37 C˚ in 5% CO2 and cultured as previously described (Gautam et al., 1996; Han
et al., 1999; Ngo et al., 2004). The AChR clusters that appeared on C2C12 and
primary myotubes were labelled with TRITC–a-BTX (1:10,000) and quantified
according to previous guidelines (Gee et al., 1994; Ngo et al., 2004). Specifically,
only AChR clusters $25 mm in their longest dimension were counted. AChR
counts represent the number of AChR clusters per myotube segment, as per our
previous studies. In all bioassays, treatment with n-agrin and neuregulin-1 involved
the addition of neuregulin-1 in the continued presence of n-agrin unless otherwise
stated. Statistical significance was determined by analysis of variance (ANOVA)
with Bonferroni post-hoc tests (Statgraphics Plus 3.0, Statistical Graphics Corp.,
VA). Graphs were constructed in Prism 4.01 (GraphPad Software Inc., CA).
For time-lapse imaging of AChRs, C2C12 myotubes grown on 6 cm plastic
plates were imaged in a 37 C˚, 5% CO2 humidified chamber. Cells were imaged
under a 106 (NA 0.3) EC Neofluar objective on an Axio-Observer Z1 inverted
microscope using a DSRed43 reflector (Carl Zeiss Inc., Oberkochen, Germany).
Cells were treated with 10 nM n-agrin to induce AChR clustering. TRITC–a-BTX
(1:10,000) was added at the same time as n-agrin. Time-lapse images were
captured on an Axiocam MR3 camera (Carl Zeiss Inc.) at 10-minute intervals for
12 hours over six random fields within each experiment. AChRs were considered
to be a large AChR cluster when they were $25 mm in their longest dimension
(i.e. continual staining of the longest dimension in the cluster).
For ErbB2 staining, C2C12 myotubes were grown on glass coverslips in 24-well
plates. Myotubes were treated with 1 nM n-agrin for 4 hours prior to incubation
with Alexa-Fluor-555–a-BTX (1:500) for 1 hour at 37 C˚ in 5% CO2. Cells were
washed twice with room-temperature PBS prior to fixation with 4%
paraformaldehyde–phosphate buffer for 5 minutes at room temperature. Cells
were washed twice with room-temperature PBS and blocked for 30 minutes with
2% BSA–PBS–0.05% Tween 20. Myotubes were incubated overnight at 4 C˚ with
rabbit anti-ErbB2 (1:100). Cells were washed three times with room-temperature
PBS prior to incubation with Alexa-Fluor-488-conjugated goat anti-rabbit IgG
(1:500) for 1.5 hours at room temperature. They were then washed a further three
times with room-temperature PBS before being mounted with Prolong Gold anti-
fade (Invitrogen). The negative control for rabbit ErbB2 receptor primary antibody
staining in C1C12 myotubes was obtained by omission of the primary antibody
and incubation with an Alexa-Fluor-488-conjugated goat anti-rabbit IgG secondary
antibody (supplementary material Fig. S2). ErbB2 and AChRs were imaged using
a Zeiss LSM Meta 510 upright confocal microscope with a Plan-Apochromat 636
(NA 1.4) oil objective (Carl Zeiss Inc.).
MuSK immunoprecipitation
Immunoprecipitation of MuSK was conducted as previously described (Cole et al.,
2010). C2C12 myotubes that were grown on 6 cm plates were lysed (50 mM Tris-
HCl, 150 mM NaCl, 0.1% SDS, 2 mM EDTA, 10 mM NaF, 10 mM Na4P2O4,
1 mM Na3VO4, 1% NP40 and protease inhibitor; cat. no. 836170001, Roche,
Basel, Switzerland) and pre-cleared before coupling MuSK to 10 ml affinity
purified human anti-human MuSK, per sample. The antigen complex was
precipitated with 50 ml protein-G–Sepharose beads. Pellets were washed three
times in lysis buffer: once with 1 M NaCl buffer, once with no NaCl buffer and
once in 50 mM Tris (pH 8). Samples were resolved by SDS-PAGE and transferred
to nitrocellulose membranes. Membranes were blocked in 2% BSA–TBS-T and
incubated overnight with anti-phosphotyrosine antibody, 4G10 (1:1000 in 1%
BSA–TBS-T). Anti-4G10 was detected with sheep anti-mouse IgG HRP (1:10,000
in 1% BSA–TBS-T). Blots were stripped and re-probed with affinity-purified
sheep anti-MuSK (1:125 in 2.5% skimmed milk in TBS-T) and detected with
rabbit anti-sheep IgG HRP (1:2000 in 2.5% skimmed milk in TBS-T) to verify
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equal loading of MuSK protein. Controls included omission of anti-MuSK
antibody from the immunoprecipitation step and substitution of control human IgG
(10 mg/ml).
Densitometric analyses of immuno-reactive bands were carried out using ImageJ
software (Abramoff et al., 2004). The integrated pixel value of each protein band
was obtained by multiplying its intensity value by its area value. The integrated
pixel value for each protein band was first normalized to that of the corresponding
immuno-band stained for MuSK. The normalized integrated pixel values were then
compared with the integrated pixel value of the MuSK phosphorylation band that
was induced by maximal (10 nM n-agrin) treatment (designated a value of 100%
MuSK phosphorylation in Fig. 7B) or the integrated pixel value of the MuSK
phosphorylation band that was induced by 1 nM n-agrin with 3 nM neuregulin-1
(designated a value of 100% in Fig. 8B). Data were analyzed using ANOVA with
Bonferroni post-hoc tests, and graphs were constructed in Prism 4.01 (GraphPad
Software Inc.).
Quantitative real-time PCR
RNA was extracted and prepared from myotubes grown on 6 cm plates using an
RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s
instructions. Reverse transcription, primer selection and quantitative real-time
PCR for the AChRa subunit and MuSK RNAs were preformed as previously
described (Cole et al., 2010). The identity of the PCR products was confirmed by
agarose gel electrophoresis and sequencing.
Ultrasound-guided microinjections
Time-mated C57Bl/6 female mice from University of Queensland Biological
Resource animal house were anaesthetized with isoflurane (Provet, QLD,
Australia) in oxygen (1.5–2% induction and maintenance) through a nose cone,
and anaesthesia was assessed and monitored by suppression of the foot-withdrawal
reflex. E15 embryos were imaged by micro-ultrasound (Vevo-770TM,
VisualSonics, Ontario, Canada) in real-time. Microinjection experiments
performed with the aid of a microinjection rail system and 40 MHz transducer
probe (RMV711, VisualSonics), were modified from the method described
previously (Slevin et al., 2006). The mother’s abdominal cavity was opened to
allow access to each uterine horn. PBS or neuregulin-1 (33 nM) mixed with
fluorescent beads (FluoresbriteH yellow–green microspheres, 2 mm diameter;
Polysciences Inc., Warrington, PA) was administered (690 nl to 1 ml) to the
sternomastoid muscle at 69 nl/second (Nanoject II, Drummond Scientific
Company, Broomall, PA) per embryo. The mother’s abdominal cavity was
sutured closed after all embryos were micro-injected. Buprenorphine diluted in
saline was administered (0.1 mg/kg, subcutaneous) to the mother for pain
management. Mothers were killed 4 hours post microinjection. Mice were first
rendered unconscious by anaesthesia (2.5 mg ketamine and 0.5 mg Xylazine per
20 g mouse, intraperitoneally) followed by cervical dislocation after the foot-
withdrawal reflex was completely suppressed. Two adult females were used in this
study. Embryos were dissected, anaesthetized on ice and killed by exposure of the
thoracic cavity. The shoulders and head of each embryo were dissected and
mounted in optimal cutting temperature medium (OCT, Sakura, Tokyo, Japan). A
total of 12, E15 embryos were used.
Microscopy and quantification of ErbB, muscle fiber area, AChRs and
innervation
For ErbB2 and ErbB3 receptors, E15 sternomastoid muscles were fixed in 4%
paraformaldehyde–phosphate buffer for 40 minutes at room temperature and
washed three times for 10 minutes with PBS. Cryosections (16 mm thick) were
obtained and stored at 220 C˚. Sections were blocked with 2% goat serum, 0.5%
BSA and 0.5% Triton X-100 in PBS for 30 minutes. Sections were incubated with
ErbB2 or ErbB3 antibodies (1:100; Santa Cruz) overnight at 4 C˚ and probed for
with an Alexa-Fluor-488-conjugated goat anti-rabbit IgG (1:5000; Invitrogen).
Alexa-Fluor-555–a-BTX (1:5000; Molecular Probes) was added to the secondary
antibody mix to detect AChRs. Negative controls for rabbit ErbB2 and rabbit
ErbB3 receptor primary antibody staining of embryonic muscle were obtained by
omission of the primary antibody and incubation with an Alexa-Fluor-488-
conjugated goat anti-rabbit IgG secondary antibody (supplementary material Fig.
S2). Sections were imaged using a Zeiss LSM Meta 510 upright confocal
microscope using a Plan-Apochromat 636 (NA1.4) oil objective (Carl Zeiss Inc.).
For AChRs, samples were incubated with Alexa-Fluor-555–a-BTX (1:500) for
1 hour at room temperature, washed three times, for 10 minutes each, with PBS,
and mounted with FluoroGuardTM Anti-Fade Reagent (Bio-Rad, CA, USA).
Cryosections were imaged under a Zeiss LSM Meta 510 upright confocal
microscope using a Plan-Apochromat 206 (NA 0.8) air objective (Carl Zeiss
Inc.). To avoid biased sampling, AChRs were examined 100 mm above and below
the point of highest injected bead concentration (this point was assumed to have
the highest concentration of injectate). AChR clusters were imaged from an area in
each section that contained the highest number of AChRs. Single optical plane
images were collected for each section. The area and number of AChRs was
measured by ImageJ. The ‘analyze particles’ plugin was used to quantify the areas
and mean pixel intensities for the isolated AChRs. AChRs included for analysis
were greater than 50 pixels. Areas of AChR clusters were converted from pixels
into micrometers squared and frequency histograms were produced in Prism 4.01
(GraphPad Software Inc.) with bin values set at multiples of 5 mm2 from 0 to
50 mm2. All AChR clusters above 50 mm2 were binned into a 50+ group. Statistical
differences were calculated using the Mann–Whitney U-test.
To assess muscle fiber diameter, samples were incubated with Alexa-Fluor-555–
a-BTX (1:500) as described above, and mounted with FluoroGuardTM Anti-Fade
Reagent (Bio-Rad). Cryosections were viewed under TRITC and FITC
(fluorescein isothiocyanate) optics with a 406 (NA 0.85) air objective on an
Olympus BX60 microscope. The section that contained the highest bead density
was selected from each injected embryo. A random area (containing AChRs) was
captured with a Zeiss AxioCam MRm camera. Twenty muscle fibers in each
section were randomly selected and cross sectional area (in pixels) of each selected
muscle fiber was measured using ImageJ software. The average muscle fiber cross
sectional area of PBS-injected embryos was compared with that of neuregulin-1-
injected embryos using an unpaired t-test and Prism 4.01 (GraphPad Software
Inc.).
To assess the innervation status of AChR clusters in the injected muscles, the
coverslips were removed from the same sections, which were then immunostained
for the presence of motor axons and their terminal endings with a neurofilament
(1:1000: Sigma) and synaptophysin (1:50: DakoCytomation) primary antibody
mixture and probed for with an Alexa-Fluor-488-conjugated goat anti-rabbit IgG
(1:500) as described previously (Banks et al., 2005). Alexa-Fluor-555–a-BTX
(1:500) was added to the second antibody mix to ensure no loss of AChR labelling.
Sections were imaged using an Axio Imager 319 microscope (Carl Zeiss Inc.). The
number of AChRs associated with nerves (i.e. #5 mm away) by positive
neurofilament–synaptophysin staining was scored over the total number of
AChR clusters in the randomly selected area (the area with the greatest number
of AChR clusters). Statistical analyses were performed using unpaired t-tests in
Prism 4.01 (GraphPad Software Inc.).
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